Clinical Trial: Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects

Brief Summary: This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).

Detailed Summary: The primary objective of this pivotal study is to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.
Sponsor: Optimer Pharmaceuticals LLC

Current Primary Outcome: Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ]

Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication.


Original Primary Outcome: Cure Rate at End of Therapy

Current Secondary Outcome: Recurrence [ Time Frame: Study days 11-40 ]

Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed.


Original Secondary Outcome: Recurrence rate

Information By: Optimer Pharmaceuticals LLC

Dates:
Date Received: April 13, 2006
Date Started: May 2, 2006
Date Completion:
Last Updated: March 23, 2017
Last Verified: March 2017